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Background: Long-term intake of long-chain n-3 polyunsaturated fatty acids (n-3 PUFAs), especially eicosapentaenoic
acid (EPA) is associated with a low risk for cardiovascular disease. Phase-contrast cine cardiovascular magnetic resonance
(PC cine CMR) can assess coronary flow reserve (CFR). The present study investigates the relationship between CFR
evaluated by PC cine CMR and the serum EPA.
Methods: We studied 127 patients (male, 116 (91%); mean age, 72.2 ± 7.4 years) with known or suspected coronary
artery disease (CAD). X-ray coronary angiography revealed no significant coronary arterial stenoses (defined as luminal
diameter reduction ≥50% on quantitative coronary angiogram (QCA) analysis) in all study participants. Breath-hold PC
cine CMR images of the coronary sinus (CS) were acquired to assess blood flow of the CS both at rest and during
adenosine triphosphate (ATP) infusion. We calculated CFR as CS blood flow during ATP infusion divided by that at
rest. Patients were allocated to groups according to whether they had high (n = 64, EPA≥ 75.8 μg/mL) or low (n = 63,
EPA < 75.8 μg/mL) median serum EPA.
Results: CFR was significantly lower in the low, than in the high EPA group (2.54 ± 1.00 vs. 2.91 ± 0.98, p = 0.038).
Serum EPA positively correlated with CFR (R = 0.35, p < 0.001). We defined preserved CFR as > 2.5, which is the
previously reported lower limit of normal flow reserve without obstructive CAD. Multivariate analysis revealed that EPA
is an independent predictor of CFR > 2.5 (odds ratio, 1.01; 95% confidence interval, 1.00 – 1.02, p = 0.008).
Conclusions: The serum EPA is significantly correlated with CFR in CAD patients without significant coronary
artery stenosis.Background
Long-term intake of long-chain n-3 polyunsaturated
fatty acids (n-3 PUFAs), especially eicosapentaenoic acid
(EPA), is associated with a low risk for cardiovascular
disease [1-7]. Several reports describe that n-3 PUFAs
confer several benefits, such as antiarrhythmic effects
[8,9] and the ability to reduce platelet aggregation [10,11]
and stabilize coronary arterial plaque [12]. The GISSI-
Prevenzione trial [13] revealed that dietary n-3 PUFA* Correspondence: shingo.m12226@gmail.com
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reproduction in any medium, provided the orintake significantly prevented cardiovascular mortality in
patients with a history of myocardial infarction. The
Japan EPA Lipid Intervention Study (JELIS) [14] showed
that concurrent therapy with purified EPA and statins re-
duces the incidence of coronary events.
Phase-contrast cine cardiovascular magnetic resonance
(PC cine CMR) is a promising approach to quantifying
global myocardial blood flow in the left ventricular (LV)
myocardium without exposure to radiation [15-19]. The
accuracy of this technique has been validated in phan-
toms [20], in animals using flow probes [18] and in
humans using positron emission tomography (PET) [16].
Coronary flow reserve (CFR) calculated from CMR flowd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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amole stress is significantly impaired in patients with
hypertrophic cardiomyopathy [15], heart failure [21] and
dilated cardiomyopathy [19].
Whether or not serum EPA levels correlated with the
CFR of patients with known or suspected coronary artery
disease (CAD) remains unclear. Therefore, the present
study aimed to determine the relationship between serum
EPA and CFR in patients with CAD using PC cine CMR.
As the presence of significant coronary artery stenosis af-
fects the CFR, we enrolled the CAD patients without ≥50%
diameter stenosis on X-ray coronary angiography (CAG).
Methods
Patients
This study included 237 patients with known or suspected
CAD who were assessed by X-ray coronary angiogram and
cardiovascular magnetic resonance (CMR) including cine
CMR, PC cine CMR, late gadolinium enhancement (LGE)
CMR. Figure 1 illustrates flow chart of patient enrollment
in this study. We excluded the patients with dilated cardio-
myopathy (n = 10), severe valvular disease (n = 8), hyper-
trophic cardiomyopathy (n = 7), sarcoidosis (n = 3) and
amyloidosis (n = 1). We also excluded patients with history
of coronary artery bypass graft surgery (CABG) (n = 10)
and patients who demonstrated significant coronary arter-
ial stenoses on X-ray CAG (n = 71). Finally, 127 patients
(male, 116 (91%); mean age, 72.2 ± 7.4 years) were enrolled
in the present study. Table 1 summarizes the character-
istics of the included patients. The medical histories of
42 (33%), 64 (50%) and 72 (57%) of the patients included
myocardial infarction, angina pectoris. We allocated the
patients to groups with high (n = 64; EPA ≥ 75.8 μg/mL)
and low (n = 63; EPA < 75.8 μg/mL) median serum EPA.
Other characteristics including coronary risk factors,Figure 1 Flow chart of enrollment of study population. CAD, coronary
coronary artery bypass graft surgery.cardiovascular history and medication did not signifi-
cantly differ between the groups (Table 1). None of them
were taking purified EPA. All patients provided written,
informed consent to participate in this study, which was
approved by the local institutional review board.
CMR acquisition
CMR was performed on a 1.5-T MR system equipped with
32 channel cardiac coils (Achieva, Philips Healthcare, Best,
The Netherlands). All patients were assessed by cine CMR,
PC cine CMR and LGE CMR. Imaging was performed
after overnight fasting. Serum fatty acid measurement was
performed on the same day as CMR.
Cine CMR acquisition
Vector-electrocardiographic (VCG) monitoring leads were
positioned on supine patients and then imaging started.
Scout images were acquired in three orthogonal planes for
cardiac orientation. Vertical and horizontal long-axis cine
CMR of the LV was acquired using a steady-state free pre-
cession (SSFP) sequence. The LV volume and mass were
calculated from short-axis cine images of the LV acquired
from the apex to the base (repetition time, 4.1 ms; echo
time, 1.7 ms; flip angle, 55°; field of view, 350 × 350 mm;
acquisition matrix, 128 × 128; slice thickness, 10 mm; and
number of phases per cardiac cycle, 20).
Phase-contrast cine CMR acquisition
Cine CMR in the axial plane was obtained through the
atrioventricular groove to locate the coronary sinus
(Figure 1). The imaging plane for blood flow measure-
ment by PC cine CMR was positioned perpendicular to
the coronary sinus 2 cm from the ostium of the coronary
sinus. Phase-contrast cine CMR of the coronary sinus
was acquired during suspended shallow breath-holdingartery disease; CMR, cardiovascular magnetic resonance; CABG,
Table 1 Patient characteristics
All patients High EPA group Low EPA group *P value
(n = 127) (n = 64) (n = 63)
Age 71.6 ± 7.8 71.8 ± 7.6 70.1 ± 9.1 0.18
Male 116 (91%) 60 (94%) 56 (89%) 0.12
Height, cm 163.4 ± 7.1 162.9 ± 7.7 164.4 ± 6.5 0.29
Body weight, kg 65.4 ± 11.1 65.9 ± 11.7 64.3 ± 9.7 0.51
Body mass index, kg/m2 24.3 ± 3.0 24.6 ± 3.2 23.7 ± 2.5 0.69
Systolic BP, mmHg 137.9 ± 20.8 135.7 ± 19.2 140.5 ± 22.3 0.24
Diastolic BP, mmHg 70.7 ± 12.6 69.6 ± 13.3 71.8 ± 11.9 0.35
Heart rate, beats per minute 67.9 ± 12.4 66.3 ± 10.7 69.6 ± 13.8 0.18
Cardiovascular history
Myocardial infarction 42 (33%) 19 (30%) 23 (37%) 0.64
Angina pectoris 64 (50%) 35 (55%) 29 (46%) 0.22
Coronary risk factors
Hypertension 93 (73%) 47 (73%) 46 (73%) 0.88
Dyslipidemia 92 (72%) 46 (72%) 46 (73%) 0.84
Diabetes Mellitus 39 (31%) 20 (31%) 19 (30%) 0.89
Current smoking 16 (13%) 9 (14%) 7 (11%) 0.48
Family history of CAD 6 (5%) 3 (5%) 3 (5%) 0.92
Obesity 41 (32%) 25 (39%) 16 (25%) 0.13
Blood test results
EPA, μg/mL 85.3 ± 53.9 121.5 ± 53.3 48.4 ± 16.9 <0.001
DHA, μg/mL 139.1 ± 54.4 163.2 ± 51.9 109.0 ± 35.2 <0.001
AA, μg/mL 178.6 ± 52.9 171.0 ± 47.3 179.6 ± 52.5 0.34
Total cholesterol, mmol/L 179.0 ± 38.6 183.1 ± 36.7 172.8 ± 37.9 0.12
LDL cholesterol, mmol/L 101.9 ± 26.7 106.6 ± 31.7 100.2 ± 27.5 0.23
HDL cholesterol, mmol/L 57.3 ± 15.9 66.1 ± 64.0 53.0 ± 14.3 0.12
Triglyceride, mmol/L 179.0 ± 38.6 171.1 ± 125.1 157.6 ± 105.6 0.51
Hemoglobin, g/dL 14.3 ± 1.6 14.3 ± 1.4 14.1 ± 1.6 0.58
HbA1c, % 6.0 ± 0.9 6.0 ± 1.0 5.8 ± 0.8 0.21
eGFR, mL/min/1.73 m2 65.7 ± 14.0 64.5 ± 13.2 65.6 ± 13.6 0.65
CRP, mg/dL 0.30 ± 1.0 0.15 ± 0.21 0.42 ± 1.37 0.25
BNP, pg/dl 53.3 ± 65.0 46.6 ± 43.9 45.9 ± 63.2 0.94
Medication use
Statin 82 (65%) 41 (64%) 41 (65%) 0.86
Antiplatelet agent 108 (85%) 52 (81%) 56 (89%) 0.91
Calcium channel blocker 45 (35%) 22 (34%) 23 (37%) 0.99
β blocker 48 (38%) 21 (33%) 27 (43%) 0.26
ACE/ARB 73 (57%) 33 (52%) 40 (63%) 0.17
Values are presented as mean ± standard deviation (SD).
* P value represents significance of difference between low EPA group and high EPA group.
EPA, eicosapentaenoic acid; AA, arachidonic acid, DHA, docosahexaenoic acid; BP, blood pressure; CAD, coronary artery disease; LDL; low density lipoprotein; HDL,
high density lipoprotein, eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; BNP, brain natriuretic peptide; ACE, angiotensin converting enzyme
inhibitor; ARB angiotensin receptor blocker.
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time, 7.3 ms; echo time, 4.4 ms; flip angle, 10°; field of
view, 240 × 194 mm; acquisition matrix, 128 × 128; and
number of phases per cardiac cycle, 20). Pharmacological
stress was achieved by injecting ATP (160 μg · kg–1 · min–1)
into the left antecubital vein for 4 min. PC cine CMR im-
ages of the coronary sinus were acquired during ATP stress
and at rest. The duration between stress and resting image
acquisition was at least 10 min. All patients were asked to
refrain from caffeinated beverages for at least 24 hours
prior to CMR.
Late gadolinium enhanced image acquisition
After acquiring phase-contrast cine CMR, the pa-
tients were injected with 0.15 mmol/kg of gadopentetate
dimeglumine (Magnevist, Bayer Healthcare, Leverkusen,
Germany). Late gadolinium-enhanced CMR was obtained
in the same planes as cine images 15 min later using an in-
version recovery–prepared gradient-echo sequence. The
imaging parameters for late gadolinium-enhanced imaging
comprised: repetition time, 4.3 ms; echo time, 1.3 ms; flip
angle, 15°; field of view, 380 × 380 mm; acquisition matrix,
256 × 180; and slice thickness, 10 mm. The null point of
the normal myocardium was determined using a Look-
Locker sequence.
X-ray coronary angiography
An observer who was blinded to the results of CMR
interpreted the conventional X-ray CAG using quantita-
tive software (QangioXA, Medis, Inc., Raleigh, North
Carolina). Intracoronary administration of isosorbide
dinitrate (2 to 3 mg) was performed in all patients before
contrast injection. We performed quantitative coronary
angiography (QCA) analysis for evaluating the degree of
coronary arterial stenosis on X-ray CAG. In our trial,
significant coronary arterial stenosis was defined as re-
duction in luminal diameter ≥50% by QCA analysis.
Measurement of serum fatty acids
Blood was sampled from all patients after an overnight
fast for at least 12 h. Serum levels of EPA, AA, and doc-
osahexaenoic acid (DHA) were measured using a gas
chromatograph (GC-2010; Shimadzu, Kyoto, Japan) and
a capillary column (BPX90; Wako, Osaka, Japan) at a
central laboratory (BML, Tokyo, Japan).
Data analysis
Two observers used a workstation (Extend MR Work-
Space, Philips Healthcare) to analyze the cine MR, PC cine
MR, and LGE images. All CMR images were rendered an-
onymous and reviewed in random order. To measure the
LV cardiac mass, epi- and endocardial borders of the LV
on the short axis cines were manually traced with exclu-
sion of the papillary muscles at each anatomic level thatencompassed the LV. The LV mass was calculated by the
consensus of two observers as the sum of the myocardial
volume areas multiplied by the specific gravity (1.05 g/mL)
of the myocardial tissue [22].
The contours of the coronary sinus were manually
traced on each frame of all PC cine images to quantify
blood flow in the coronary sinus and velocity in the ad-
jacent tissue was measured for phase-offset correction.
Blood flow in the coronary sinus was calculated by inte-
grating the product of the cross-sectional area and the
mean velocity in the coronary sinus and corrected using
mean velocity in the adjacent tissue for all cardiac phases
in the cardiac cycle. In line with other studies, we also cor-
rected coronary sinus blood flow using rate pressure prod-
ucts (RPP) [16,19,23-26].
RPP mmHg‧bpmð Þ ¼ Systolic blood pressure mmHgð Þ
Heart rate beats=minð Þ
Corrected CS flow mL=minð Þ ¼ CS flow mL=minð Þ
=RPP mmHg‧bpmð Þ  7500
The ΔCS flow and CFR were calculated as:
ΔCS flow mL=minð Þ ¼ Corrected CS flow during ATP
infusion mL=minð Þ−Corrected
CS flow at rest mL=minð Þ
Coronary flow reserve CFRð Þ ¼ Corrected CS flow during
ATP infusion mL=minð Þ
=Corrected CS flow at
rest mL=minð Þ
The coronary vascular resistance (CVR) was calculated
as follows.
CVR mmHg‧min=mLð Þ ¼ mean arterial pressure
MAPð Þ mmHgð Þ=corrected
CS flow mL=minð Þ
MAP mmHgð Þ ¼ systolic BP mmHgð Þ þ 2x diastolic
BP mmHgð Þ=3
Late gadolinium-enhancement was visually assessed and
interpreted by the consensus of two observers who were
blinded to the patients’ information. The mass with LGE
was measured on short-axis slices using manual planim-
etry. The total mass of LGE was calculated by summing
the late gadolinium-enhanced mass of all sections, and the
ratio (%) of LGE is expressed as:
LGE %ð Þ ¼ Total LGE volume=Total LV wall volume
 100 %ð Þ
None of the patients had atypical enhancement de-
fined as mid-myocardial or sub-epicardial enhancement
with multifocal distribution.
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Data were statistically analyzed using SPSS software, ver-
sion 17.0 (SPSS, Inc., Chicago, IL, USA). Continuous
values are presented as means ± standard deviation (SD).
Skewed values are presented as medians with the inter-
quartile range (IQR). Normality was determined by the
Shapiro-Wilk test. Coronary flow reserve determined by
CMR was compared between the high and low EPA
groups. Differences between the groups were evaluated
using an unpaired t-test for normally distributed vari-
ables, and the Mann–Whitney U test for skewed vari-
ables. The relationship between serum fatty acids and
CFR determined by CMR was determined using Pear-
son’s correlation coefficient. Preserved CFR was defined
as CFR > 2.5 by PC cine CMR, which is the lower limit
of normal flow reserve without obstructive CAD [27].
Independent predictors of impaired CFR were evalu-
ated using univariate analysis and multivariate stepwise
analyses. Inter- and intra-observer reproducibility was
evaluated using the intraclass correlation coefficient
(ICC). P values < 0.05 were considered statistically sig-
nificant. In addition, we allocated study population into
4 groups based on presence or absence of DM and
serum EPA. We evaluated significance of difference be-




We acquired PC cine CMR from all patients in the rest-
ing state and during ATP stress (Figure 2). Figure 3
shows representative blood flow curves of the coronary
sinus at rest and during infusion. Table 2 summarizes the
CMR findings. Cine parameters such as LV end-diastolic
volume index (LVEDVI), LV end-systolic volume index
(LVESVI), LV ejection fraction (LVEF), LV mass index
did not significantly differ between the low and high EPAFigure 2 Phase-contrast cine cardiovascular magnetic resonance of th
steady state free precession (white solid line). (B) Magnitude image of coro
Blood flow in the coronary sinus appears as a low signal intensity area in (Cgroups. In addition, LGE parameters, such as presence of
LGE and percentage of LGE (%) also did not significantly
differ between the groups.
Comparison of coronary flow reserve in low and high
EPA groups
Table 3 compares coronary sinus blood flow at rest
and during ATP infusion, and CFR in the low and
high EPA/AA groups. The coronary sinus blood flow
measurements were reproducible, with ICCs of 0.93
and 0.95 for inter- and intra-observer reproducibility,
respectively. No significant difference between low and
high EPA groups was found in HR, SBP, DBP and RPP
at rest and during ATP infusion. SBP and DBP were
significantly decreased by ATP infusion both in low
and high EPA groups. Corrected coronary sinus blood
flow was significantly augmented by ATP infusion in
the low and high EPA groups (from 79.1 ± 32.4 to
191.5 ± 87.2 mL/min, p < 0.001 and from 82.3 ± 35.0 to
229.5 ± 95.0 mL/min, p < 0.001, respectively), whereas
ΔCS flow was significantly lower in the group with low
EPA (112.4 ± 73.7 vs. 147.2 ± 77.7 mL/min, p = 0.036).
Furthermore, CFR was significantly reduced in the low,
compared with the high EPA group (2.54 ± 1.00 vs.
2.91 ± 0.98, p = 0.038). We found significant difference
in CVR during ATP infusion between high and low
EPA groups (0.53 ± 0.25 vs. 0.44 ± 0.26, p = 0.049). In
addition, we divided study population into 4 groups
based on presence or absence of DM and serum EPA
(group 1, n = 44: DM(−) & EPA ≥75.8 μg/mL, group 2,
n = 44: DM(−) & EPA <75.8 μg/mL, group 3, n = 20:
DM (+) & EPA ≥75.8 μg/mL, group 4, n = 19: DM (+) &
EPA <75.8 μg/mL. CFR was highest in group 1 and low-
est in group 4 (mean CFR: 3.04 ± 1.00 in group1, 2.69 ±
1.11 in group2, 2.67 ± 1.04 in group 3, 2.39 ± 0.83). How-
ever, difference between 4 group did not show significant
difference (p = 0.16 by one-way ANOVA).e coronary sinus. (A) Axial image of the coronary sinus acquired by
nary sinus (white arrow). (C) Phase difference image of coronary sinus.
), (black arrow). CMR, cardiovascular magnetic resonance.
Figure 3 Curves of blood flow in coronary sinus. Blood flow was measured using phase-contrast cine CMR. Blue and red lines, blood flow at
rest and during ATP infusion, respectively. Coronary sinus blood flow increased about 4-fold in this patient during ATP infusion (rest vs. ATP
infusion: = 70 vs. 266 mL/min; CFR = 3.8). ATP, adenosine triphosphate; CFR, coronary flow reserve; CS, coronary sinus.
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Figure 4 shows relationships between serum fatty acids
(EPA, DHA, AA) and CFR evaluated by CMR. Serum
levels of EPA and DHA correlated significantly and posi-
tively (R = 0.35 and p < 0.001, R = 0.29 and p = 0.001, and
R = 0.35 and p < 0.001, respectively), whereas those of AA
correlated significantly and negatively (R = −0.18, p = 0.046)
with CFR.
Univariate and multivariate analyses of predictors
of reduced CFR
Table 4 shows the results of the univariate and multi-
variate analyses of predictors of CFR > 2.5 determined by
PC cine CMR. Univariate analysis selected history of dia-
betes mellitus, serum EPA, LVMI on cine CMR as signifi-
cant predictors of CFR > 2.5. Variables with p values < 0.05
in the univariate analysis were included in the multiple




LVEDVI, mL/m2 73.9 ± 24.9
LVESVI, mL/m2 33.2 ± 19.9
LVSVI, mL/m2 40.8 ± 10.5
LVEF, % 57.1 ± 12.1
LV mass index, g/m2 56.3 ± 16.9
Late Gadolinium enhanced CMR
Presence of LGE 66 (52%)
LGE (%) 10.6 ± 14.2
Values are presented as mean ± standard deviation (SD).
* P value represents significance of difference between low EPA group and high EP
EPA, eicosapentaenoic acid; CMR, cardiovascular magnetic resonance; LV, left ventri
volume index; EF, ejection fraction; LGE, late gadolinium enhancement.was a significant determinant CFR > 2.5 (odds ratio (OR),
1.01; 95% confidence interval (CI), 1.00 – 1.02; p = 0.008).
Other independent variables comprised history of diabetes
mellitus (OR, 0.39; 95%CI, 0.17 – 0.89; p = 0.026), LVMI
(OR, 0.97; 95%CI, 0.95 – 0.99; p = 0.024).
Discussion
This is the first investigation of the relation between
CFR evaluated as changes in coronary sinus flow in-
duced by ATP infusion, and serum EPA. In patients
without significant coronary arterial stenosis on X-ray cor-
onary angiography, serum EPA and DHA levels signifi-
cantly and positively correlated with CFR. Multivariate
linear regression analysis showed that the EPA was an in-
dependent predictor of impairment of CFR evaluated by
CMR. These results indicated that the serum EPA plays
an important role in the regulation of CFR in patients
with CAD.igh EPA group Low EPA group * P value
(n = 64) (n = 63)
71.7 ± 21.8 76.1 ± 27.7 0.33
31.0 ± 19.1 35.4 ± 20.7 0.21
40.8 ± 8.6 40.8 ± 12.3 0.98
58.9 ± 11.7 55.3 ± 16.9 0.094
57.8 ± 17.0 54.8 ± 16.9 0.32
32 (50%) 34 (54%) 0.65
9.0 ± 13.1 12.2 ± 15.2 0.21
A group.
cle; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; SVI, stroke
Table 3 Coronary sinus blood flow at rest and during ATP infusion in groups with low and high EPA
All patients, (N = 127) High EPA group, (n = 64) Low EPA group, (n = 63) * P-value
HR at rest, bpm 68 ± 12 66 ± 11 70 ± 14 0.14
HR during ATP infusion, bpm 71 ± 12 69 ± 11 73 ± 12 0.086
SBP at rest, mmHg 138 ± 21 136 ± 19 140 ± 22 0.22
SBP during ATP infusion, mmHg 117 ± 20** 117 ± 19** 117 ± 22** 1.00
DBP at rest, mmHg 71 ± 13 69 ± 13 72 ± 12 0.33
DBP during ATP infusion, mmHg 62 ± 12** 62 ± 13** 72 ± 12** 0.87
RPP at rest 9432 ± 2505 9047 ± 2206 9825 ± 2739 0.11
RPP during ATP infusion 8303 ± 2105** 8116 ± 2111** 8508 ± 2100** 0.34
cCS flow at rest (mL/min) 77.4 ± 32.7 82.3 ± 35.0 79.1 ± 32.4 0.59
cCS flow during ATP infusion (mL/min) 203.3 ± 89.6** 229.5 ± 95.0** 191.5 ± 87.2** 0.021
Δ cCS flow (mL/min) 125.9 ± 75.8 147.2 ± 77.7 112.4 ± 73.7 0.011
Coronary flow reserve 2.75 ± 1.03 2.91 ± 0.98 2.54 ± 1.00 0.038
CVR at rest, mmHg‧min/mL 1.37 ± 0.54 1.33 ± 0.60 1.41 ± 0.47 0.73
CVR during ATP infusion mmHg‧min/mL 0.49 ± 0.26** 0.44 ± 0.26** 0.53 ± 0.25** 0.049
Data are expressed as mean ± SD. * P-value represents significance of the difference between low EPA group and high EPA group. ** P < 0.05 vs. at rest.
HR = heart rate, ATP = adenosine triphosphate. SBP = systolic blood pressure, DBP = diastolic blood pressure, RPP, rate pressure product; ATP, adenosine triphosphate;
EPA, eicosapentaenoic acid; CS, coronary sinus, CVR = coronary vascular resistance.
cCS flow = corrected coronary sinus flow, Δ cCS flow = cCS flow during ATP infusion – cCS flow at rest. Coronary flow reserve = cCS flow during ATP infusion / cCS
flow at rest × 100. MAP = (SBP + DBPx2)/3, CVR =MAP/cCS flow.
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of impairment of CFR
The results of multivariate regression analysis in this study
revealed that presence of DM, LVMI and serum EPA were
the independent predictors of preserved CFR (CFR > 2.5).
The CFR is an index of coronary microvascular function
in patients without epicardial coronary arterial stenosis,
therefore, we assessed the relationship between micro-
vascular function and serum EPA concentration. It’s well
known that the women more frequently develop micro-
vascular disease (MVD) in comparison to men, however,
men and women who have coronary MVD often have con-
ventional risk factors, such as hypertension and DM [28].
The presence of DM was an independent predictor of CFR
in this study, and the result is in line with previous study.Figure 4 Relationship between serum fatty acid and coronary flow re
resonance. Serum levels of EPA and DHA significantly and positively corre
significantly and negatively correlate with CFR determined by PC cine CMR (R =
EPA, eicosapentaenoic acid.However, presence of hypertension and presence of dyslip-
idemia were not independent predictors of CFR. The main
reason is that the ACEI/ARB treatment for hypertension
or statin treatment for dyslipidemia was already started.
These drugs potentially have benefirial effects to MVD
[28]. The serum EPA might play an important role for the
regulation of CFR, and EPA drug treatment potentially im-
prove the microvascular function in patients with MVD.
LV hypertrophy is another important mechanism of
CFR impairment. presence of significant coronary arter-
ial stenosis that results in dilatation already at rest. The
patients with LV hypertrophy have a higher level of auto-
regulated blood flow at rest to meet the demand of an
increased myocardial mass [29]. Therefore, CFR is reduced
because resting flow is already increased closer to theserve evaluated by phase-contrast cine cardiovascular magnetic
late with CFR (R = 0.35, p < 0.001; R = 0.29, p = 0.001). Serum AA levels
−0.18, p = 0.046). CFR coronary flow reserve; DHA, docosahexaenoic acid;
Table 4 Predictors of coronary flow reserve >2.5 determined by univariate and multivariate analyses
Univariate analysis Multivariate analysis
Odds ratio 95% CI P value Odds ratio 95% CI P value
Patients’ characteristics
Age, per year 1.01 0.97 – 1.05 0.65 Not selected
Male, men 1.58 0.43 – 5.68 0.49 Not selected
Systolic blood pressure, per mmHg 0.99 0.97 – 1.01 0.99 Not selected
Diastolic blood pressure, per mmHg 0.98 0.95 – 1.02 0.31 Not selected
Heart rate. Per bpm 0.98 0.95 – 1.01 0.19 Not selected
History of myocardial infarction , yes 1.27 0.57 – 2.86 0.55 Not selected
History of angina pectoris, yes 1.56 0.71 – 3.56 0.26 Not selected
Coronary risk factors
Hypertension, yes 0.69 0.26 – 0.69 0.45 Not selected
Dyslipidemia, yes 0.67 0.25 – 1.77 0.42 Not selected
Diabetes Mellitus, yes 0.35 0.16 – 0.77 0.009 0.39 0.17 - 0.89 0.026
Current smoking, yes 1.49 0.50 – 4.45 0.48 Not selected
Family history of CAD, yes 1.21 0.23 – 6.40 0.82 Not selected
Obesity, BMI≥ 25 kg/m2, yes 1.41 0.66 – 3.00 0.37 Not selected
Blood testing
EPA, per μg/mL 1.01 1.00 – 1.02 0.017 1.01 1.00 – 1.02 0.008
Total cholesterol, per mmol/L 1.00 0.99 – 1.01 0.62 Not selected
LDL cholesterol, per mmol/L 1.00 0.99 – 1.01 0.93 Not selected
HDL cholesterol, per mmol/L 1.02 0.99 – 1.04 0.21 Not selected
Triglyceride, per mmol/L 1.00 0.99 – 1.00 0.97 Not selected
HbA1c, per% 0.92 0.63 – 1.34 0.68 Not selected
eGFR, per mL/min/1.73 m2 0.99 0.97 – 1.03 0.94 Not selected
CRP, per mg/dL 0.57 0.18 – 1.80 0.34 Not selected
BNP, per pg/dl 1.00 0.99 – 1.01 0.66 Not selected
Cine CMR
LVEDVI, per mL/m2 1.00 0.99 – 1.01 0.75 Not selected
LVESVI, per mL/m2 0.99 0.98 – 1.01 0.32 Not selected
LVEF, per% 1.03 1.00 – 1.06 0.066 Not selected
LVMI, per g/m2 0.97 0.95 – 1.00 0.019 0.97 0.95-0.99 0.024
Late Gadolinium enhanced CMR
Presence of LGE, yes 0.65 0.32 – 1.32 0.24 Not selected
LGE (%), per% 0.97 0.95 – 1.02 0.35 Not selected
The variables with p value < 0.05 in the univariate analysis were included in the multivariate analysis.
CI, confidence interval; CFR, coronary flow reserve; LGE, late gadolinium enhancement; BMI, body mass index; EPA, eicosapentaenoic acid; LDL; low density
lipoprotein; HDL, high density lipoprotein, eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; BNP, brain natriuretic peptide; CMR, cardiovascular
magnetic resonance; LV, left ventricle; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; SVI, stroke volume index; EF, ejection fraction; LVMI, left
ventricular mass index.
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dictor of CFR in the current study, which is in line
with previous study.
Clinical significance of serum fatty acid on CAD prevention
Epidemiological studies have shown that the incidence
of acute myocardial infarction is substantially loweramong non-emigrated inhabitants of Greenland (5.3%),
than in individuals from the United States (40.4%) and
Denmark (34.7%), with age- and sex adjusted death rates
for ischemic heart disease [30]. This is mainly due to the
composition of Eskimo food in north western Greenland,
which is dominated by n-3 PUFA, such as EPA and DHA
(ratios of n-3 PUFA in total Eskimo and Danish dietary
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[30]. The randomized controlled GISSI-Prevenzione
trial showed that dietary n-3 PUFA intake can reduce
the rate of cardiovascular death among patients after a
recent (≤ 3 months) myocardial infarction [13]. The
large, randomized JELIS control trial found that that
administering pure EPA together with statin therapy
reduced the risk of developing coronary events to 19%
[14]. However, precisely how n-3 PUFA prevents CAD
remains unknown. Some reports have shown favorable
effects of n-3 PUFA on the cardiovascular system. Leaf
et al. showed that n-3 PUFA helped to prevent arrhythmic
deaths, including sudden cardiac death [31]. Ghio et al.
showed that n-3 PUFA significantly increases LV systolic
function in patients with symptomatic heart failure of any
etiology [31]. In addition, Moertl et al. found that n-3
PUFA administered for 3 months exerts a dose-dependent
increase in the LVEF of patients with chronic heart failure.
Moreover, high-dose n-3 PUFA intervention significantly
improves endothelial function and decreases interleukin 6
levels [32]. We found that the serum EPA is an independ-
ent predictor of impaired CFR evaluated by PC cine CMR.
This finding indicates that improved CFR might be an im-
portant mechanism through which n-3 PUFA prevents
cardiovascular events.
Clinical implications
In this study, we enrolled the CAD patients without ≥50%
diameter stenosis on X-ray CAG, and assessed the micro-
vascular function by calculating the CFR by PC-cine
CMR. It is important to evaluate the disease severity in pa-
tients with non-obstructive CAD, because the prognosis
of MVD is not as benign as commonly thought [28]. Ran-
domized placebo-controlled studies have demonstrated
that angiotensin-converting enzyme inhibitors, statins etc.
relieve symptoms, vascular dysfunction, or both [28]. In
the current study, most of our patients were administered
with aspirin and statins, and had relatively low LDL chol-
esterol levels. Regardless, the EPA significantly correlated
with CFR, and it was an independent predictor of reduced
CFR. These results suggest that EPA therapy will help to
improve CFR and prevent cardiovascular events through
different mechanisms from statins or antiplatelet drugs. A
further prospective interventional study is required to clar-
ify this point.
Study limitation
First, this was a single center study with a relatively
small patient cohort. Although CFR assessment by PC
cine CMR is non-invasive and useful, CMR is contrain-
dicated for patients implanted with pacemakers or car-
diovascular defibrillators and those with claustrophobia.
Such patients were excluded from the present study.
Second, we excluded the CAD patients with significantcoronary arterial stenosis (diameter reduction ≥50% by
QCA analysis). Therefore, the findings of this study can
only be applied to the CAD patients without ≥50% diam-
eter stenosis. The reason to exclude the patients with sig-
nificant CAD was that the fall of blood pressure induced
by ATP should have too much compromised coronary
flow with the risk to produce an unwanted myocardial is-
chemia. Third, CVR assessed in the current study mean
the resistance throughout the entire cardiac cycle, in-
cluded the systolic period during which a compressive re-
sistance is added to the resistance due to the coronary
vasomotor tone, usually indicated as coronary “vascular”
resistance (auto-regulative resistance).
Conclusion
Serum EPA is significantly correlated with CFR in CAD
patients without significant coronary artery stenosis.
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